{"id":"combination-600","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of Combination 600 is not well-documented, but it is believed to work by targeting multiple pathways involved in the disease process.","oneSentence":"Combination 600 is a combination of two or more drugs that work together to treat a specific condition.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:27:11.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 2 clinical trials for Combination 600 are ongoing for the treatment of [specific condition]"}]},"trialDetails":[{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":"Lymphoma","enrollment":129},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06819176","phase":"PHASE1","title":"Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-01-20","conditions":"Human Immunodeficiency Virus","enrollment":50},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT01846390","phase":"PHASE1","title":"Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2013-10-01","conditions":"Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":21},{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":"Contact With or Exposure to Human Immunodeficiency Virus","enrollment":1500},{"nctId":"NCT07492342","phase":"PHASE2","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","status":"RECRUITING","sponsor":"Jianxing He","startDate":"2026-01-29","conditions":"Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC","enrollment":30},{"nctId":"NCT06958835","phase":"NA","title":"Linezolid Plus Standard of Care","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-10-06","conditions":"Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)","enrollment":606},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT07103018","phase":"PHASE1","title":"A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)","status":"RECRUITING","sponsor":"K36 Therapeutics, Inc.","startDate":"2025-11-21","conditions":"Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC","enrollment":144},{"nctId":"NCT07487129","phase":"PHASE4","title":"Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-08-25","conditions":"Breast Cancer","enrollment":206},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT06680154","phase":"NA","title":"Induction and Stabilization of Gamma Oscillations With 40 Hz External Brain Stimulation","status":"COMPLETED","sponsor":"The National Brain Mapping Laboratory (NBML)","startDate":"2021-07-13","conditions":"Alzheimer Disease, Working Memory, EEG Brain Oscillations","enrollment":30},{"nctId":"NCT06377852","phase":"PHASE3","title":"The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2024-10-29","conditions":"Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT04613596","phase":"PHASE2, PHASE3","title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","status":"RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2020-12-02","conditions":"Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer","enrollment":806},{"nctId":"NCT03585465","phase":"PHASE1, PHASE2","title":"Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-03-26","conditions":"Childhood Solid Tumor","enrollment":63},{"nctId":"NCT07477691","phase":"PHASE4","title":"Immune Modulation During Palynziq® Treatment in Adults (IMPALA)","status":"NOT_YET_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2026-03-31","conditions":"Phenylketonuria","enrollment":12},{"nctId":"NCT07476677","phase":"PHASE2","title":"Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-04-01","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT07292753","phase":"NA","title":"Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-12-15","conditions":"Nocturnal Enuresis, Vitamin D Deficiency","enrollment":90},{"nctId":"NCT06576843","phase":"PHASE2","title":"INDV-6001 Multiple-Dose Pharmacokinetic Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2024-09-17","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":123},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":"HER2 Positive Breast Cancer","enrollment":654},{"nctId":"NCT07472478","phase":"PHASE2","title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-15","conditions":"Lung Cancer (NSCLC), KRAS G12C Lung Cancer","enrollment":32},{"nctId":"NCT04253561","phase":"PHASE1","title":"Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2020-02-25","conditions":"Metastatic Breast Cancer","enrollment":17},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT07085767","phase":"PHASE3","title":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2025-11-03","conditions":"Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":1000},{"nctId":"NCT07470203","phase":"","title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":"HER2-positive Breast Cancer","enrollment":42},{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT05179876","phase":"PHASE3","title":"A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option","status":"RECRUITING","sponsor":"Actelion","startDate":"2022-05-04","conditions":"Hypertension, Pulmonary","enrollment":280},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT07466225","phase":"","title":"HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":150},{"nctId":"NCT07035249","phase":"PHASE1, PHASE2","title":"DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-12-16","conditions":"DCSZ11, Solid Tumors, HNSCC","enrollment":9},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT07463677","phase":"PHASE2","title":"Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Lung Cancer (NSCLC)","enrollment":55},{"nctId":"NCT07198841","phase":"PHASE2","title":"IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation","status":"RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-11-03","conditions":"Lung Cancer (Non-Small Cell)","enrollment":48},{"nctId":"NCT06059846","phase":"PHASE3","title":"A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2023-12-21","conditions":"Urinary Tract Infection, Acute Pyelonephritis","enrollment":1690},{"nctId":"NCT07460310","phase":"NA","title":"Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"Ankle Sprain, Ankle (Ligaments); Instability (Old Injury), Pain Management","enrollment":200},{"nctId":"NCT07460947","phase":"PHASE1, PHASE2","title":"A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder","status":"NOT_YET_RECRUITING","sponsor":"Mclean Hospital","startDate":"2026-03","conditions":"Borderline Personality Disorder (BPD)","enrollment":20},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer","enrollment":1050},{"nctId":"NCT07374224","phase":"PHASE1","title":"A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2026-03-05","conditions":"Clinical Pharmacology","enrollment":28},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT04734990","phase":"PHASE1, PHASE2","title":"Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-07","conditions":"Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2","enrollment":44},{"nctId":"NCT07450599","phase":"PHASE2","title":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-04-15","conditions":"High-Risk Localized Prostate Cancer","enrollment":250},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT06541262","phase":"PHASE1, PHASE2","title":"Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2024-10-30","conditions":"Neuroblastoma, Ewing Sarcoma, Osteosarcoma","enrollment":104},{"nctId":"NCT02689258","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2016-02-23","conditions":"Postoperative Pain","enrollment":277},{"nctId":"NCT06063538","phase":"EARLY_PHASE1","title":"Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-02-15","conditions":"Atrial Fibrillation, Post-Op Complication","enrollment":63},{"nctId":"NCT07190300","phase":"PHASE1, PHASE2","title":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-01-13","conditions":"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":155},{"nctId":"NCT07342283","phase":"PHASE2","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2026-02-25","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30},{"nctId":"NCT06101342","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":181},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT07430592","phase":"PHASE2","title":"This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria","status":"NOT_YET_RECRUITING","sponsor":"R. Kiplin Guy","startDate":"2026-03-20","conditions":"Malaria, Malaria Vivax, Radical Cure","enrollment":104},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT04024462","phase":"PHASE3","title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT07410559","phase":"PHASE2","title":"Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-07-01","conditions":"Breast Cancer","enrollment":189},{"nctId":"NCT07414212","phase":"PHASE1, PHASE2","title":"Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)","status":"RECRUITING","sponsor":"Biogipuzkoa Health Research Institute","startDate":"2025-11-25","conditions":"Amyotrophic Lateral Sclerosis","enrollment":90},{"nctId":"NCT06420271","phase":"NA","title":"Effects of Cerebellar tACS-iTBS in Ataxia","status":"RECRUITING","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2025-05-01","conditions":"Ataxia","enrollment":30},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT07300475","phase":"PHASE1","title":"Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT07405671","phase":"PHASE4","title":"Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-09","conditions":"Atrial Fibrillation (AF), Coronary Artery Disease","enrollment":988},{"nctId":"NCT06627530","phase":"PHASE4","title":"COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2025-02-17","conditions":"Prostate Cancer","enrollment":144},{"nctId":"NCT05149365","phase":"PHASE3","title":"Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-12-22","conditions":"Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":190},{"nctId":"NCT03858231","phase":"PHASE4","title":"Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery","status":"RECRUITING","sponsor":"Sanford Health","startDate":"2018-10-29","conditions":"Knee Injuries, Pain, Postoperative, Opioid Use","enrollment":148},{"nctId":"NCT03778229","phase":"PHASE2","title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-01-09","conditions":"Carcinoma","enrollment":367},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT07398638","phase":"PHASE1, PHASE2","title":"Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-28","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":122},{"nctId":"NCT05661578","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2023-05-04","conditions":"PD-L1-selected Solid Tumors","enrollment":64},{"nctId":"NCT05049512","phase":"NA","title":"Low Dose Multi-Nut Oral Immunotherapy in Pre-schoolers With a Multi-Nut Allergy","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-16","conditions":"Allergy, Nut","enrollment":12},{"nctId":"NCT06175390","phase":"PHASE2","title":"Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2024-03-27","conditions":"Triple Negative Breast Cancer","enrollment":81},{"nctId":"NCT06631521","phase":"PHASE1","title":"Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer","status":"RECRUITING","sponsor":"AdventHealth","startDate":"2024-10-22","conditions":"Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery","enrollment":30},{"nctId":"NCT01796197","phase":"PHASE2","title":"Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-08","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT05052996","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-10-05","conditions":"HIV-1 Infection","enrollment":142},{"nctId":"NCT02876302","phase":"PHASE2","title":"Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-01-24","conditions":"Inflammatory Breast Cancer (IBC)","enrollment":23},{"nctId":"NCT07383818","phase":"PHASE2","title":"Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-02-01","conditions":"HR Positive/HER2 Low Breast Cancer","enrollment":111},{"nctId":"NCT04619797","phase":"PHASE2, PHASE3","title":"A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":542},{"nctId":"NCT04294810","phase":"PHASE3","title":"A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-03-04","conditions":"Non-Small Cell Lung Cancer","enrollment":620},{"nctId":"NCT02143466","phase":"PHASE1","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-08-05","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":344},{"nctId":"NCT06144944","phase":"PHASE3","title":"Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-01-17","conditions":"Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma","enrollment":160},{"nctId":"NCT07170800","phase":"PHASE2","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","status":"RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2025-09-19","conditions":"Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":60},{"nctId":"NCT05645692","phase":"PHASE2","title":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-04-13","conditions":"Urothelial Cancer","enrollment":204},{"nctId":"NCT06627712","phase":"PHASE3","title":"SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-01","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":318},{"nctId":"NCT04648033","phase":"PHASE1","title":"Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-12-07","conditions":"Locally Advanced Non-Small Cell Lung Cancer","enrollment":21},{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT03697304","phase":"PHASE2","title":"Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-19","conditions":"Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors","enrollment":211},{"nctId":"NCT03156114","phase":"PHASE1","title":"This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-06-13","conditions":"Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":172},{"nctId":"NCT04139434","phase":"PHASE1","title":"Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML","status":"COMPLETED","sponsor":"Newave Pharmaceutical Inc","startDate":"2020-07-06","conditions":"AML/MDS, CMML, Relapse","enrollment":32},{"nctId":"NCT05746481","phase":"PHASE2","title":"Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases","status":"TERMINATED","sponsor":"Liza Villaruz, MD","startDate":"2023-08-10","conditions":"Non-small Cell Lung Cancer","enrollment":3},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT05909332","phase":"PHASE3","title":"Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-20","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":764},{"nctId":"NCT07351487","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-25","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":37},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":"Immunodeficiencies, Primary Immunodeficiencies (PID), Agammaglobulinemia","enrollment":50},{"nctId":"NCT03563716","phase":"PHASE2","title":"A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2018-08-10","conditions":"Non-small Cell Lung Cancer","enrollment":135},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT06682195","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-10-09","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":35},{"nctId":"NCT04746183","phase":"PHASE1, PHASE2","title":"AGILE (Early Phase Platform Trial for COVID-19)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2020-07-03","conditions":"Covid19","enrollment":600},{"nctId":"NCT07339839","phase":"PHASE1, PHASE2","title":"Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"NSCLC Stage IV, KRAS G12C","enrollment":42},{"nctId":"NCT05074147","phase":"PHASE3","title":"Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2)","status":"WITHDRAWN","sponsor":"Tourcoing Hospital","startDate":"2022-05-01","conditions":"Osteomyelitis - Foot","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19231,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Combination 600","genericName":"Combination 600","companyName":"Nuon Therapeutics, Inc.","companyId":"nuon-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Combination 600 is a combination of two or more drugs that work together to treat a specific condition. Used for Phase 2 clinical trials for Combination 600 are ongoing for the treatment of [specific condition].","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}